{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:44:31Z","timestamp":1786729471682,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Hospital Clinic of Barcelona","award":["Emili Letang - Josep Font 2024"],"award-info":[{"award-number":["Emili Letang - Josep Font 2024"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FIS PI24\/01776"],"award-info":[{"award-number":["FIS PI24\/01776"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40121-026-01392-7","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T20:04:38Z","timestamp":1782158678000},"page":"2561-2573","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Use of Isavuconazole in the Treatment of Cryptococcosis: A Real-World Case Series"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3223-670X","authenticated-orcid":false,"given":"Marta","family":"Albanell-Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Vergara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Martinez-Urrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Garcia-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ulldemolins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Mensa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lex","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Bodro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"1392_CR1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1086\/649858","volume":"50","author":"JR Perfect","year":"2010","unstructured":"Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases Society of America. Clin Infect Dis. 2010;50:291\u2013322. https:\/\/doi.org\/10.1086\/649858.","journal-title":"Clin Infect Dis"},{"key":"1392_CR2","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.1016\/S1473-3099(23)00731-4","volume":"24","author":"CC Chang","year":"2024","unstructured":"Chang CC, Harrison TS, Bicanic TA, Chayakulkeeree M, Sorrell TC, Warris A, et al. Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM. Lancet Infect Dis. 2024;24:e495\u2013512. https:\/\/doi.org\/10.1016\/S1473-3099(23)00731-4.","journal-title":"Lancet Infect Dis"},{"key":"1392_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/myc.12747","volume":"61","author":"F Bongomin","year":"2018","unstructured":"Bongomin F, Oladele RO, Gago S, Moore CB, Richardson MD. A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species. Mycoses. 2018;61:290\u20137. https:\/\/doi.org\/10.1111\/myc.12747.","journal-title":"Mycoses"},{"key":"1392_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jiac.2022.10.010","volume":"29","author":"S Kohno","year":"2023","unstructured":"Kohno S, Izumikawa K, Takazono T, Miyazaki T, Yoshida M, Kamei K, et al. Efficacy and safety of isavuconazole against deep-seated mycoses: a phase 3, randomized, open-label study in Japan. J Infect Chemother. 2023;29:163\u201370. https:\/\/doi.org\/10.1016\/j.jiac.2022.10.010.","journal-title":"J Infect Chemother"},{"key":"1392_CR5","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","volume":"16","author":"FM Marty","year":"2016","unstructured":"Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16:828\u201337. https:\/\/doi.org\/10.1016\/S1473-3099(16)00071-2.","journal-title":"Lancet Infect Dis"},{"key":"1392_CR6","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","volume":"387","author":"JA Maertens","year":"2016","unstructured":"Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387:760\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(15)01159-9.","journal-title":"Lancet"},{"key":"1392_CR7","doi-asserted-by":"publisher","first-page":"572","DOI":"10.5414\/CP202434","volume":"54","author":"A Schmitt-Hoffmann","year":"2016","unstructured":"Schmitt-Hoffmann A, Desai A, Kowalski D, Pearlman H, Yamazaki T, Townsend R. Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH. Int J Clin Pharmacol Ther. 2016;54:572\u201380. https:\/\/doi.org\/10.5414\/CP202434.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1392_CR8","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1128\/AAC.02819-15","volume":"60","author":"A Desai","year":"2016","unstructured":"Desai A, Kovanda L, Kowalski D, Lu Q, Townsend R, Bonate PL. Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi. Antimicrob Agents Chemother. 2016;60:5483\u201391. https:\/\/doi.org\/10.1128\/AAC.02819-15.","journal-title":"Antimicrob Agents Chemother"},{"key":"1392_CR9","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/cid\/ciw305","volume":"63","author":"GR Thompson","year":"2016","unstructured":"Thompson GR, Rendon A, Ribeiro dos Santos R, Queiroz-Telles F, Ostrosky-Zeichner L, Azie N, et al. Isavuconazole treatment of cryptococcosis and dimorphic mycoses. Clin Infect Dis. 2016;63:356\u201362. https:\/\/doi.org\/10.1093\/cid\/ciw305.","journal-title":"Clin Infect Dis"},{"key":"1392_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2024.10.002","volume":"31","author":"T Kawaguchi","year":"2025","unstructured":"Kawaguchi T, Kitamura A, Kimura M, Rikitake Y, Iwao C, Iwao K, et al. Successful treatment of disseminated cryptococcosis with liposomal amphotericin B and isavuconazole in an adult living with HIV: a case report and literature review. J Infect Chemother. 2025;31:102534. https:\/\/doi.org\/10.1016\/j.jiac.2024.10.002.","journal-title":"J Infect Chemother"},{"key":"1392_CR11","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.radcr.2022.11.011","volume":"18","author":"LG Ramanzini","year":"2023","unstructured":"Ramanzini LG, de Medeiros SDP, Lima LMFV, dos Santos MVR, Herbster EA, Ara\u00fajo GDAS, et al. Cerebral cryptococcoma successfully treated by isavuconazole in an immunocompetent patient: a case report. Radiol Case Rep. 2023;18:824\u20139. https:\/\/doi.org\/10.1016\/j.radcr.2022.11.011.","journal-title":"Radiol Case Rep"},{"key":"1392_CR12","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11046-019-00374-3","volume":"184","author":"KA Linder","year":"2019","unstructured":"Linder KA, Gandhi TN, Miceli MH. Treatment failure of isavuconazole in a patient with cryptococcosis. Mycopathologia. 2019;184:667\u201370. https:\/\/doi.org\/10.1007\/s11046-019-00374-3.","journal-title":"Mycopathologia"},{"key":"1392_CR13","doi-asserted-by":"publisher","first-page":"i26","DOI":"10.1093\/jac\/dkx446","volume":"73","author":"A Mourad","year":"2018","unstructured":"Mourad A, Perfect JR. Tolerability profile of the current antifungal armoury. J Antimicrob Chemother. 2018;73:i26\u201332. https:\/\/doi.org\/10.1093\/jac\/dkx446.","journal-title":"J Antimicrob Chemother"},{"key":"1392_CR14","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1093\/jac\/dkae088","volume":"79","author":"F Bergmann","year":"2024","unstructured":"Bergmann F, W\u00f6lfl-Duchek M, Jorda A, Al Jalali V, Leutzendorff A, Sanz-Codina M, et al. Pharmacokinetics of isavuconazole at different target sites in healthy volunteers after single and multiple intravenous infusions. J Antimicrob Chemother. 2024;79:1169\u201375. https:\/\/doi.org\/10.1093\/jac\/dkae088.","journal-title":"J Antimicrob Chemother"},{"key":"1392_CR15","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/mmy\/myab035","volume":"59","author":"MR Davis","year":"2021","unstructured":"Davis MR, Chang S, Gaynor P, McCreary EK, Allyn P. Isavuconazole for treatment of refractory coccidioidal meningitis with concomitant cerebrospinal fluid and plasma therapeutic drug monitoring. Med Mycol. 2021;59:939\u201342. https:\/\/doi.org\/10.1093\/mmy\/myab035.","journal-title":"Med Mycol"},{"key":"1392_CR16","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1093\/jac\/dkz050","volume":"74","author":"F Lamoth","year":"2019","unstructured":"Lamoth F, Mercier T, Andr\u00e9 P, Pagani JL, Pantet O, Maduri R, et al. Isavuconazole brain penetration in cerebral aspergillosis. J Antimicrob Chemother. 2019;74:1751\u20133. https:\/\/doi.org\/10.1093\/jac\/dkz050.","journal-title":"J Antimicrob Chemother"},{"key":"1392_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2025.107619","volume":"66","author":"Z Tan","year":"2025","unstructured":"Tan Z, Zhang N, Liang B, Bai N, Cai Y. Therapeutic drug monitoring of isavuconazole: trends and update. Int J Antimicrob Agents. 2025;66:107619. https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107619.","journal-title":"Int J Antimicrob Agents"},{"key":"1392_CR18","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1128\/AAC.04055-14","volume":"59","author":"A Espinel-Ingroff","year":"2015","unstructured":"Espinel-Ingroff A, Chowdhary A, Gonzalez GM, Guinea J, Hagen F, Meis JF, et al. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27\u2013A3 broth microdilution method. Antimicrob Agents Chemother. 2015;59:666\u20138. https:\/\/doi.org\/10.1128\/AAC.04055-14.","journal-title":"Antimicrob Agents Chemother"},{"key":"1392_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/mmy\/myz103","volume":"58","author":"S Schwartz","year":"2020","unstructured":"Schwartz S, Cornely OA, Hamed K, Marty FM, Maertens J, Rahav G, et al. Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system. Med Mycol. 2020;58:417\u201324. https:\/\/doi.org\/10.1093\/mmy\/myz103.","journal-title":"Med Mycol"},{"key":"1392_CR20","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/jac\/dkad038","volume":"78","author":"KE Stott","year":"2023","unstructured":"Stott KE, Ahmadu A, Kajanga C, Moyo M, Gondwe E, Chimang\u2019anga W, et al. Population pharmacokinetics and CSF penetration of flucytosine in adults with HIV-associated cryptococcal meningoencephalitis. J Antimicrob Chemother. 2023;78:1015\u201322. https:\/\/doi.org\/10.1093\/jac\/dkad038.","journal-title":"J Antimicrob Chemother"},{"key":"1392_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2026.107743","volume":"67","author":"F Bergmann","year":"2026","unstructured":"Bergmann F, Prager M, Pracher L, Jorda A, Haselwanter P, Zeitlinger M. Tissue pharmacokinetics of antifungal drugs: a review. Int J Antimicrob Agents. 2026;67:107743. https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107743.","journal-title":"Int J Antimicrob Agents"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01392-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01392-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01392-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:24:19Z","timestamp":1786728259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01392-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1392"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01392-7","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"22 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Carolina Garcia-Vidal has received honoraria for talks on behalf of Gilead Sciences, MSD, Pfizer, Shionogi, bioM\u00e9rieux, Viatris, Mundipharma, and Advanz Pharma, as well as grant support from Gilead Sciences and Mundipharma. \u00c1lex Soriano has received honoraria for talks on behalf of Merck Sharp and Dohme, Pfizer, Novartis, Angelini, Menarini, and Gilead Sciences, as well as grant support from Pfizer and Gilead Science. \u00c1lex Soriano is co-Editor-in-Chief of\n                      Infectious Diseases and Therapy\n                      . \u00c1lex Soriano was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Marta Albanell-Fern\u00e1ndez, Andrea Vergara, Ana Martinez-Urrea, Josep Mensa, Marta Ulldemolins, and Marta Bodro have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Review Committee of the Hospital Clinic of Barcelona (HCB\/2026\/0388). The data used in this study were fully anonymized, and the requirement for informed consent was waived by the ethics committee because of the retrospective nature of the study.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}